^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    1d
    TEMPO-LT: TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Stanford University
    New P1/2 trial
    2d
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    2d
    Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (clinicaltrials.gov)
    P4, N=48, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    THYMO B: Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients (clinicaltrials.gov)
    P=N/A, N=49, Completed, University Hospital, Brest | Unknown status --> Completed
    Trial completion
    3d
    Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy (clinicaltrials.gov)
    P1, N=24, Enrolling by invitation, Stanford University | Trial completion date: May 2028 --> Dec 2030 | Trial primary completion date: May 2025 --> Dec 2030 | Not yet recruiting --> Enrolling by invitation
    Enrollment open • Trial completion date • Trial primary completion date
    8d
    MYCOHYPE: An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis (clinicaltrials.gov)
    P4, N=144, Active, not recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    prednisolone
    8d
    D3461C00040: A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-nave and Biologic-nave Systemic Lupus Erythematosus (2025-523670-17-00)
    P2/3, N=55, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    8d
    CSAGCD: Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, Baylor College of Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    8d
    AGORAC: Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure (clinicaltrials.gov)
    P3, N=300, Recruiting, Nantes University Hospital | Trial completion date: Oct 2026 --> Dec 2028 | Trial primary completion date: Aug 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    9d
    Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy With Subsequent Diagnosis of Mantle Cell Lymphoma. (PubMed, Cureus)
    A diagnosis of statin-associated anti-HMGCR IMNM was established, and treatment with mycophenolate mofetil and intravenous immunoglobulin resulted in partial biochemical improvement...Further evaluation revealed mantle cell lymphoma with bone marrow involvement, IGH::CCND1 rearrangement, and TP53 deletion, consistent with high-risk disease. In this context, continued clinical and laboratory monitoring is appropriate in inflammatory myopathy, and new hematologic abnormalities warrant further evaluation.
    Journal
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
    |
    TP53 deletion
    14d
    Fludarabine Based RIC for Bone Marrow Failure Syndromes (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Children's Hospital of Philadelphia | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    15d
    TAOIST: TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Hospices Civils de Lyon | N=300 --> 600
    Enrollment change
    |
    KEAP1 (Kelch Like ECH Associated Protein 1)